| Stephen Cheukwan Lau, DDS | |
|
18 E. 22nd St., Lombard, IL 60148 | |
| (630) 629-9398 | |
| (630) 629-3919 |
| Full Name | Stephen Cheukwan Lau |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 18 E. 22nd St., Lombard, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003136961 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 16129 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Cheukwan Lau, DDS 18 E. 22nd St., Lombard, IL 60148 Ph: (630) 629-9398 | Stephen Cheukwan Lau, DDS 18 E. 22nd St., Lombard, IL 60148 Ph: (630) 629-9398 |
News Archive
"Reaching for a game-changer, President Barack Obama is beset by conflicting goals in a prime-time address Wednesday expected to detail just how he wants to expand health care coverage and lower medical costs while signaling to a deeply divided Congress that he's ready to deal. And show the public he's in control," The Associated Press reports.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Sydney scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function.
Patients with bipolar disorder are more likely to respond to lithium if the treatment is started early in the course of the condition, say researchers.
The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research.
› Verified 6 days ago
Joel Robert Shepperd, M.D. General Practice Medicare: May Accept Medicare Assignments Practice Location: 400 E 22nd St, Suite F, Lombard, IL 60148 Phone: 630-792-9311 Fax: 630-792-9316 |